Cyr61 (CCN1) is a secreted, cysteine-rich, heparinbinding protein belonging to the CCN (cysteine-rich 61 (Cyr61), connective tissue growth (CTFG), nephroblastoma overexpressed (NOV)) family of growth regulators (Brigstock et al., 2003) . In addition to the abovementioned three members, other members of this family include WISP-1-3. All CCN family members are highly conserved, with structural similarities to extracellular matrix-associated molecules. They are composed of multifunctional modular domains with sequence homologies to insulin-like growth factor-binding protein, von Willebrand factor type C repeat, thromobospondin type I repeat and growth factor cysteine knots (Menendez et al., 2003) .
Originally identified as a serum-inducible factor in BALB/c 3T3 mouse fibroblast (O'Brien et al., 1990) , Cyr61 has been found to be associated with the cell surface as well as the extracellular matrix (Yang and Lau, 1991) , and to mediate diverse functions including extracellular matrix formation, differentiation, cell proliferation, adhesion, migration, survival, as well as angiogenesis and tumorigenesis (for reviews, see Brigstock, 1999; Lau and Lam, 1999; Perbal, 2001; Menendez et al., 2003) . Cyr61 has been reported to bind to several integrin receptors including a v b 3 , a v b 5 , aIIbb 3 and a 6 b 1 , and thus may function through the integrin pathway Jedsadayanmata et al., 1999; Chen et al., 2000; Grzeszkiewicz et al., 2001) .
The role of Cyr61 in breast cancer development and progression has been examined in detail. Cyr61 is highly expressed in breast tumor specimens, especially in tumors of advanced stage as well as tumors with lymph node involvement, suggesting its involvement in invasive and metastatic tumors (Tsai et al., 2000; Sampath et al., 2001a; Xie et al., 2001a, b) . Curiously, although Cyr61 was found to be overexpressed in 40% of estrogenreceptor (ER)-negative invasive breast carcinomas in one study (Tsai et al., 2000) , it was reported to be strongly correlated with ER-positive breast carcinomas in another study (Xie et al., 2001b) . In breast cancer cell lines, Cyr61 augments a metastatic phenotype by promoting cell proliferation in soft agar, cell migration, invasion and outgrowth of cells in Matrigel matrix (Xie et al., 2001a; Tsai et al., 2002) . Fewer studies have examined the role of Cyr61 in other cancers. Similar to the observation in breast cancer cell lines, Cyr61 was also found to enhance tumor growth of a gastric adenocarcinoma cell line, RF-1 (Babic et al., 1998) . Conversely, Cyr61 was shown to behave as a tumor suppressor gene in an NSCLC cell line, promoting growth arrest and upregulation of p53, p21 WAF1 and pRB2/p130, as well as attenuating tumor growth in nude mice (Tong et al., 2001) . In contrast to the observations in breast cancers, Cyr61 expression was reported to be downregulated in prostate cancer (Pilarsky et al., 1998) , uterine leiomyomas (Sampath et al., 2001b) and nonsmall-cell lung carcinomas (NSCLC) (Tong et al., 2001) .
In the present study, we examined the expression of the Cyr61 gene in 34 tumors and adjacent paired normal liver tissues in hepatocellular carcinoma (HCC) patients using reverse transcribed real-time polymerase chain reaction (PCR). Significantly, we found Cyr61 expression in tumors to be downregulated by at least twofold compared to adjacent normal tissues in 27 of 34 HCC patient samples (B80%) examined (Table 1, columns 1 and 2). Our observation of downregulation of Cyr61 gene expression in HCC patients is consistent with an earlier report (Xu et al., 2001 ) that utilized a cDNA array to identify differentially expressed genes, but contradicts another report (Hirasaki et al., 2001 ) which did not observe differential expression of this gene in HCC patients. A possible reason for the seeming discrepancy could be that Hirasaki et al. (2001) utilized a nonquantitative gel-based RT-PCR strategy at 40 cycles, while Xu et al. (2001) and our present study utilized a hybridization-based strategy and a semiquantitative reversed transcribed real-time PCR method, respectively.
The human Cyr61 (hCyr61) gene maps to chromosome 1p (Jay et al., 1997) , a region implicated in several different malignancies (Simon et al., 1991; Shin et al., 1993; Gehring et al., 1995) and poor prognosis in breast cancer (Hainsworth et al., 1992) . To understand the Cyr61 promoter microsatellite repeat variability B Wang et al regulation of Cyr61 gene expression, we investigated its promoter. The Cyr61 promoter has been delineated to a region of approximately 1 kb in the 5 0 flanking region of the gene (Schutze et al., 2001) . One characteristic feature of the human Cyr61 promoter is the presence of two polymorphic d(CA) dinucleotide repeats, each preceded by an HNF3b-and an ATF-binding site (Schutze et al., 2001) (Figure 1 ). In the mouse, the Cyr61 promoter contains only a single stretch of d(CA) repeat located at a different position within the promoter (Latinkic et al., 1991) .
Dinucleotide repeats have also been reported within or close to the promoters of other genes including those encoding matrix-metalloproteinase 9 (Peters et al., 1999; Shimajiri et al., 1999; Huang et al., 2003) , acetyl-CoA carboxylase (Tae et al., 1994) , cytosolic phospholipase A2 (Miyashita et al., 1995) , epidermal growth factor receptor (Gebhardt et al., 1999) , insulin-like growth factor-1 (IGF-1) (Rotwein et al., 1986) , Kv1.5 (Mori et al., 1995) , rat prolactin (Naylor and Clark, 1990) , rat nucleolin (Rothenburg et al., 2001 ) and human HMGA2 (Borrmann et al., 2003) . These dinucleotide repeats were found to modulate promoter activity both positively (Hamada et al., 1984; Shimajiri et al., 1999; Borrmann et al., 2003; Huang et al., 2003) and negatively (Naylor and Clark, 1990; Tae et al., 1994; Mori et al., 1995; Gebhardt et al., 1999; Rothenburg et al., 2001) . The dinucleotide repeats near the IGF-1 promoter have also been reported to be associated with a risk for development of breast cancer (Yu et al., 2001) .
We thus postulated that the two stretches of d(CA) repeats downstream of the HNF3b-and ATF-binding sites may play important roles in modulating the Cyr61 promoter activity. We proceeded to investigate the effect of length of the d(CA) repeats in modulating Cyr61 promoter activity by performing transient transfection assays in several human cell lines using various Cyr61 promoter constructs, each containing a different total d(CA) repeat length isolated from different patient samples (Table 2) . Promoter activity was determined as the amount of b-galactosidase activity (OD/sec) normalized against enhanced green fluorescence protein (EGFP) expression (RFU) (Figure 2a) . A promoter construct containing 40 d(CA) repeats showed reduced activity in the KB3-1 cell line, compared to a construct containing 37 repeats (Po0.01) (Figure 2b ). Constructs containing larger d(CA) repeats resulted in more pronounced attenuation of promoter activity (Po0.001) (Figure 2b ). The promoter constructs containing the smallest and largest repeats (37 and 54 d(CA)s), respectively, were transfected into two additional cell lines, the HepG2 HCC cell line and the All patient samples were obtained in accordance with the Ethics Review Board Guidelines of the National Cancer Center, Singapore. RNA was isolated as described . cDNA was synthesized by reverse transcription of total RNA with Superscript II reverse transcriptase (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. Real-time PCR was performed using the QuantiTectt SYBR s Green PCR Kit (Qiagen, Hilden, Germany) in a Rotor-Gene 2000 Real-Time Thermal Cycler (Corbett Research, NSW, Australia). Amplification reactions contained 50 ng of cDNA template, 0.25 pmol/ml each of the forward and reverse primers for Cyr61 (Table 2a , b) or the b-actin control (Table 2c , d), and 10 ml of 2 Â PCR Master Mix (Qiagen) in a total volume of 20 ml. Thermal cycling conditions for Cyr61 were an initial denaturation at 951C for 15 min followed by 40 cycles of 941C for 30 s, 601C for 30 s and 721C for 30 s, while b-actin amplification involved an initial denaturation at 951C for 15 min followed by 40 cycles at 951C for 15 s, 551C for 20 s and 721C for 40 s. SYBR s green fluorescence was measured after each extension step. Standard curves for Cyr61 and b-actin were generated using serial dilution of plasmids containing segments of Cyr61 or b-actin cDNA. The linear range for Cyr61 expression was determined to be between 10 6 and 10 9 copies (r 2 ¼ 0.999), while b-actin expression was linear between 10 4 and 10 8 copies of the gene (r 2 ¼ 0.999). Cyr61 expression was normalized against b-actin. All RT-PCR reactions were performed in triplicate. Cyr61 gene expression was defined as significantly different when the expression levels (mean7s.d.) of the paired tumor and adjacent normal tissues differed by a factor of greater than 2.
b d(CA) dinucleotide repeat length determination is as described in Figure 4 . c Microsatellite analyses of two unlinked dinucleotide repeats (D7S2502 and D7S486) were performed as controls. The forward primer of D7S2502 (Table 2g ) and the reverse primer of D7S486 (Table 2j) were labeled with HEX and FAM, respectively. Each 20 ml reaction contained 40 ng of genomic DNA, 8 pmol of each primer for D7S2502 (Table 2g , h), 2.4 pmol of each primer for D7S486 (Table 2i , j), 0.2 mM of each dNTP, 1 U HotStarTaqt DNA polymerase (Qiagen) and 2 ml of 10 Â PCR buffer (Qiagen). The multiplex PCR conditions were an initial 15 min denaturation at 941C, followed by 35 cycles of 951C for 30 s, 551C for 30 s and 721C for 30 s, ending with a final extension temperature at 721C for 6 min. Automated fragment analyses were similarly performed as described above Cyr61 promoter microsatellite repeat variability B Wang et al MCF-7 breast carcinoma cell line. As observed with KB3-1 cells, the 54-repeat promoter construct displayed weaker activity compared to the 37-repeat construct when tested in HepG2 cells (Po0.001) (Figure 2c ). However, no significant difference in promoter activity was observed when the two constructs were tested in MCF-7 cells (P>0.05) (Figure 2c ). These results suggest an inverse relationship between the length of the Cyr61 promoter d(CA) repeats and promoter activity in specific cell types, including hepatic cells. This differential effect on different cell lines could be due to the differential availability of factors in the different cell types regulating the influence of d(CA) repeats on Cyr61 promoter activity.
The observed inverse relationship between d(CA) repeat length and strength of Cyr61 promoter activity could be directly due to the d(CA) repeat itself or due to changes in the nucleotide spacing between the two 
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H N F 3 β S R F S P 1 A P 1 H N F 3 β E 2 F A T F H N F 3 β C A r e p e a t C A r e p e a t H N F 3 β A T F promoter, while EGFP gene is driven by a constitutive promoter for normalization of transfection efficiency. Wild-type Cyr61 promoter and various in vitro mutagenized variants were cloned into the construct. Cyr61 promoter fragments containing 37-54 d(CA) repeats (constructs Cyr61ca37-54) were amplified directly from HCC samples using primers k and l (Table 2) . PCR mutagenesis methods using primers listed in Table 2 were utilized to generate artificial mutant promoter fragments. These mutant constructs were either deleted for one or more sequences, such as the HNF3b, ATF and d(CA) repeats, or had one or more of these segments replaced by random or modified sequence segments of equal length. The random/modified sequences were verified not to contain putative binding sites using the MatInspector Program http://www.genomatix.de/. All plasmid constructs containing normal and mutant Cyr61 promoters were sequenced across the PCR amplified regions to exclude PCR-induced nucleotide mis-incorporations prior to use. Promoter-reporter constructs were transfected into either the HeLa subclone, KB3-1, the HepG2 HCC cell line or the MCF-7 breast cancer cell line, using either calcium phosphate co-precipitation as described previously (Lee et al., 2000) or Superfectt Transfection Reagent (Qiagen). b-Gal activity was quantitated in a kinetic assay using chlorphenol red-b-D-galactopyranoside (CPRG) as substrate and measured at 1-min intervals over 60 min at 570 nm in a SpectraMAX PLUS microplate reader (Molecular Devices, Sunnyvale, CA, USA), while EGFP fluorescence was measured at 509 nm in a SpectraMAX Gemini microplate reader (Molecular Devices) after excitation at 488 nm. (Chen et al., 1994) .
To distinguish between these possibilities, we tested the effect of substituting the 37 d(CA) repeats with 74 random nucleotides. Replacement of the d(CA) repeats with random sequences resulted in a significant attenuation of Cyr61 promoter activity (Po0.001) (Figure 3a , row b), suggesting that the d(CA) repeats are important for Cyr61 promoter activity. Alternating purine-pyrimidine repeats, for example, d(CA) repeats, but not random sequences, have been reported to form alternative DNA structures, for example, Z-DNA (Rich et al., 1984; Wells, 1988; Rich, 1993) and to reside near transcription start sites (Schroth et al., 1992) . Specific proteins that bind to Z-DNA (Schwartz et al., 1999 (Schwartz et al., , 2001 ) may play a role in fine-tuning transcriptional control of such genes. Curiously, when the d(CA) TGAC  TGAC  TGTTT  TGTTT   23  14  -gal  23  14  -gal -gal   TGAC  TGAC  TGTTT  TGTTT  TGAC  TGAC  TGTTT  TGTTT   23  14  -gal TGAC  TGAC  TGTTT  TGTTT  TGAC  TGAC  TGTTT  TGTTT   23 Cyr61 promoter microsatellite repeat variability B Wang et al repeats as well as the flanking ATF-and HNF3b-binding sites were replaced by an equal number of random nucleotides, Cyr61 promoter activity was significantly increased (Po0.01) (Figure 3a, row c) .
Similarly, substitution of a 45 d(CA) repeat and flanking ATF-and HNF3b-binding sites with random sequences of equal length resulted in significantly increased Cyr61 promoter activity (Po0.01) (Figure 3a, rows d, e) . (Table 2e ,f). The forward primer was labeled with the fluorescent dye, FAM, at the 5 0 end to facilitate automated fragment analyses. Each 25 ml PCR reaction contained 40 ng of genomic DNA, 5 pmol of each primer, 0.2 mM of each dNTP, 1.25 U of HotStar Taqt DNA polymerase (Qiagen) and 2.5 ml of 10 Â PCR buffer (Qiagen). Thermal cycling conditions were an initial 15 min denaturation at 951C, followed by 35 cycles of 951C for 30 s, 581C for 30 s and 721C for 30 s, ending with a final extension temperature at 721C for 10 min. Each PCR product (0.5-1 ml) was combined with 0.25 ml of GeneScant-500 ROXt size standard (Applied Biosystems) and HiDi formamide (Applied Biosystems) was added to a final volume of 11 ml. Sample mixtures were denatured at 951C for 5 min before being analysed on an ABI PRISM s 3100 Genetic Analyzer (Applied Biosystems). Amplified products were sized with the aid of Genescant analysis software (Applied Biosystems). All amplification and Genescan analyses were performed at least in duplicate. (Figure 3b , row e) compared to the wild-type 37 d(CA) repeat promoter. Together, these results suggest that the d(CA) repeats and adjacent ATF-and HNF3b-binding sites are not essential for Cyr61 promoter activity, but rather serve to modulate promoter activity. HNF3b-binding sites and longer d(CA) repeats have an attenuating or silencing effect on promoter activity, while the ATF-binding sites act as enhancer elements. Hence, our in vitro studies support the notion that each of the two tandem stretches contains an enhancer element (ATF), a silencer element (HNF3b), and a variable moderator of promoter activity (d(CA) repeat). It would be interesting to evaluate if these observations still hold true in the context of nucleosomally organized chromatinized DNA when the various reporter constructs are integrated into the host genome.
Microsatellite instability is a common feature in many cancers and has been implicated in carcinogenesis and cancer progression. We thus investigated the variability of d(CA) repeats within the Cyr61 promoter in the tumors and adjacent normal liver of HCC patients. We found that the allele sizes differed between tumors and their paired adjacent normal tissues in B26% (9/34) of the HCC patients (Table 1 , column 4) (Figure 4b and c) . Interestingly, in B21% (7/34) of HCC patients, more than two allele sizes were observed, in either the tumor or the adjacent normal tissue or both, indicative of somatic mosaicism of this repeat locus (Table 1 , column 5) (Figure 4c ). In five of the seven HCC patients, somatic mosaicism was observed only in the tumor tissues and not in the adjacent normal tissues. There was evidence of loss of heterozygosity (LOH) in a further 12% (4/34) of tumor tissues (Table 1 , column 5) (Figure 4d ). All results were confirmed by repeat PCR amplification and allele sizing of all samples.
To determine if the observed microsatellite instability, including somatic mosacism and LOH, at the Cyr61 promoter locus in HCC patients is a global genomic instability phenomenon in these patients, we performed microsatellite analysis at two other d(CA) repeat loci (D7S2502 and D7S486) unlinked to the Cyr61 promoter locus (Table 1, columns 6, 7) . No evidence of microsatellite instability was observed for these two repeat loci either in the tumor or in the adjacent normal tissues of HCC patients. The D7S486 and D7S2502 allele sizes were identical between tumor and adjacent normal liver tissues of 33/34 HCC patients. In the sole exception (patient 26), the tumor tissue showed two alleles of 13 and 20 repeats for D7S2502, but the adjacent normal liver displayed only the 20-repeat allele. Nonetheless, the results suggest that the observed Cyr61 promoter microsatellite instability is unlikely due to a global genomic instability.
These observations together with our in vitro promoter characterization suggest the possible functional significance of d(CA) repeats in regulating Cyr61 gene expression. Unfortunately, except for HCC patients 10, 14 and 24, whereby downregulation of the Cyr61 gene expression is correlated with higher d(CA) repeat allele acquired either through somatic mosaicism or LOH of the lower repeat allele in the tumor tissue but not the adjacent normal liver tissue (Table 1 , columns 1-5), no other obvious correlation can be observed between the number of d(CA) repeats and differences in Cyr61 gene expression between the tumor and adjacent normal liver tissues.
A possible explanation for the above observation is that d(CA) repeats alone may account for a small percentage of the observed downregulation of Cyr61 gene expression. Our in vitro characterization of the role of the two stretches of repeats suggests that regulation of Cyr61 expression is much more complex and probably involves the ATF-binding sites as enhancer as well as HNF3b-binding sites as silencer. Hence, the differential availability and expression of various factors binding to the d(CA) repeats (e.g. ADAR1 or DLM) (Schwartz et al., 1999 (Schwartz et al., , 2001 , ATF-or HNF3b-binding sites in the tumor versus the normal tissues may differentially influence Cyr61 promoter activity. In preliminary experiments, we observed that expression of ATF3, which is capable of binding to ATF-binding sites, was downregulated to different extents in the tumors of several HCC patients tested compared to the adjacent normal liver. In addition, HNF3b expression was reported to be upregulated in the tumors of HCC patients (Xu et al., 2001) . Hence, in addition to the characterization of the number and structure of d(CA) repeats, detailed characterization of the expression of ATF3, HNF3b as well as proteins capable of binding to d(CA) repeats as well as ATF-or HNF3b-binding sites may have to be taken into consideration to better understand the regulation of Cyr61 gene expression.
Another possible explanation could be that somatic mutations in regions of Cyr61 promoter other than the two stretches of repeats or the availability of additional factors binding to other sites within the promoter may also account for the differential Cyr61 expression between the tumors and adjacent normal liver tissues of HCC patients. In addition, epigenetic events like differential methylation may also account for the downregulation of Cyr61 gene expression in the tumors of HCC patients. Cyr61 promoter is CG-rich, containing at least 49 CGs within a region of approximately 1 kb and hence detailed examination of methylation status of this promoter in the tumor versus the adjacent normal may also help clarify the observed downregulation of the promoter.
In summary, we observed increased d(CA) microsatellite repeat instability at the Cyr61 promoter locus compared to unlinked d(CA) microsatellite repeats in the tumors of HCC patients. We also demonstrate that the length of d(CA) dinucleotide at the Cyr61 promoter is inversely correlated with its promoter activity. However, we found that the microsatellite repeat alone cannot fully account for the downregulation of Cyr61 expression that we observed in the tumors of HCC patients.
